Cargando…

Elevated expression of CDK4 in lung cancer

BACKGROUND: The aim of the present study was to analyze the expression of Cyclin-dependent kinase 4 (CDK4) in lung cancer and its correlation with clinicopathologic features. Furthermore, the involvement of CDK4-mediated cell cycle progression and its molecular basis were investigated in the pathoge...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Aibing, Wu, Bin, Guo, Jinsong, Luo, Weiren, Wu, Dong, Yang, Huiling, Zhen, Yan, Yu, Xiaoli, Wang, Hao, Zhou, Ying, Liu, Zhen, Fang, Weiyi, Yang, Zhixiong
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094221/
https://www.ncbi.nlm.nih.gov/pubmed/21477379
http://dx.doi.org/10.1186/1479-5876-9-38
_version_ 1782203519949864960
author Wu, Aibing
Wu, Bin
Guo, Jinsong
Luo, Weiren
Wu, Dong
Yang, Huiling
Zhen, Yan
Yu, Xiaoli
Wang, Hao
Zhou, Ying
Liu, Zhen
Fang, Weiyi
Yang, Zhixiong
author_facet Wu, Aibing
Wu, Bin
Guo, Jinsong
Luo, Weiren
Wu, Dong
Yang, Huiling
Zhen, Yan
Yu, Xiaoli
Wang, Hao
Zhou, Ying
Liu, Zhen
Fang, Weiyi
Yang, Zhixiong
author_sort Wu, Aibing
collection PubMed
description BACKGROUND: The aim of the present study was to analyze the expression of Cyclin-dependent kinase 4 (CDK4) in lung cancer and its correlation with clinicopathologic features. Furthermore, the involvement of CDK4-mediated cell cycle progression and its molecular basis were investigated in the pathogenesis of lung cancer. METHODS: Using immunohistochemistry analysis, we analyzed CDK4 protein expression in 89 clinicopathologically characterized lung cancer patients (59 males and 30 females) with ages ranging from 36 to 78 years and compared them to 23 normal lung tissues. Cases with cytoplasmic and nuclear CDK4 immunostaining score values greater than or equal to 7 were regarded as high expression while scores less than 7 were considered low expression. The correlation between the expression level of CDK4 and clinical features was analyzed. Furthermore, we used lentiviral-mediated shRNA to suppress the expression of CDK4 and investigate its function and molecular mechanism for mediating cell cycle progression. RESULTS: The expression level of CDK4 protein was significantly increased in lung cancer tissues compared to normal tissues (P < 0.001). In addition, high levels of CDK4 protein were positively correlated with the status of pathology classification (P = 0.047), lymph node metastasis (P = 0.007), and clinical stage (P = 0.004) of lung cancer patients. Patients with higher CDK4 expression had a markedly shorter overall survival time than patients with low CDK4 expression. Multivariate analysis suggested the level of CDK4 expression was an independent prognostic indicator (P < 0.001) for the survival of patients with lung cancer. Use of lentiviral-mediated shRNA to inhibit the expression of CDK4 in lung cancer cell line A549 not only inhibited cell cycle progression, but also dramatically suppressed cell proliferation, colony formation, and migration. Furthermore, suppressing CDK4 expression also significantly elevated the expression of cell cycle regulator p21 CONCLUSION: Overexpressed CDK4 is a potential unfavorable prognostic factor and mediates cell cycle progression by regulating the expression of p21 in lung cancer
format Text
id pubmed-3094221
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30942212011-05-14 Elevated expression of CDK4 in lung cancer Wu, Aibing Wu, Bin Guo, Jinsong Luo, Weiren Wu, Dong Yang, Huiling Zhen, Yan Yu, Xiaoli Wang, Hao Zhou, Ying Liu, Zhen Fang, Weiyi Yang, Zhixiong J Transl Med Research BACKGROUND: The aim of the present study was to analyze the expression of Cyclin-dependent kinase 4 (CDK4) in lung cancer and its correlation with clinicopathologic features. Furthermore, the involvement of CDK4-mediated cell cycle progression and its molecular basis were investigated in the pathogenesis of lung cancer. METHODS: Using immunohistochemistry analysis, we analyzed CDK4 protein expression in 89 clinicopathologically characterized lung cancer patients (59 males and 30 females) with ages ranging from 36 to 78 years and compared them to 23 normal lung tissues. Cases with cytoplasmic and nuclear CDK4 immunostaining score values greater than or equal to 7 were regarded as high expression while scores less than 7 were considered low expression. The correlation between the expression level of CDK4 and clinical features was analyzed. Furthermore, we used lentiviral-mediated shRNA to suppress the expression of CDK4 and investigate its function and molecular mechanism for mediating cell cycle progression. RESULTS: The expression level of CDK4 protein was significantly increased in lung cancer tissues compared to normal tissues (P < 0.001). In addition, high levels of CDK4 protein were positively correlated with the status of pathology classification (P = 0.047), lymph node metastasis (P = 0.007), and clinical stage (P = 0.004) of lung cancer patients. Patients with higher CDK4 expression had a markedly shorter overall survival time than patients with low CDK4 expression. Multivariate analysis suggested the level of CDK4 expression was an independent prognostic indicator (P < 0.001) for the survival of patients with lung cancer. Use of lentiviral-mediated shRNA to inhibit the expression of CDK4 in lung cancer cell line A549 not only inhibited cell cycle progression, but also dramatically suppressed cell proliferation, colony formation, and migration. Furthermore, suppressing CDK4 expression also significantly elevated the expression of cell cycle regulator p21 CONCLUSION: Overexpressed CDK4 is a potential unfavorable prognostic factor and mediates cell cycle progression by regulating the expression of p21 in lung cancer BioMed Central 2011-04-11 /pmc/articles/PMC3094221/ /pubmed/21477379 http://dx.doi.org/10.1186/1479-5876-9-38 Text en Copyright ©2011 Wu et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Wu, Aibing
Wu, Bin
Guo, Jinsong
Luo, Weiren
Wu, Dong
Yang, Huiling
Zhen, Yan
Yu, Xiaoli
Wang, Hao
Zhou, Ying
Liu, Zhen
Fang, Weiyi
Yang, Zhixiong
Elevated expression of CDK4 in lung cancer
title Elevated expression of CDK4 in lung cancer
title_full Elevated expression of CDK4 in lung cancer
title_fullStr Elevated expression of CDK4 in lung cancer
title_full_unstemmed Elevated expression of CDK4 in lung cancer
title_short Elevated expression of CDK4 in lung cancer
title_sort elevated expression of cdk4 in lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094221/
https://www.ncbi.nlm.nih.gov/pubmed/21477379
http://dx.doi.org/10.1186/1479-5876-9-38
work_keys_str_mv AT wuaibing elevatedexpressionofcdk4inlungcancer
AT wubin elevatedexpressionofcdk4inlungcancer
AT guojinsong elevatedexpressionofcdk4inlungcancer
AT luoweiren elevatedexpressionofcdk4inlungcancer
AT wudong elevatedexpressionofcdk4inlungcancer
AT yanghuiling elevatedexpressionofcdk4inlungcancer
AT zhenyan elevatedexpressionofcdk4inlungcancer
AT yuxiaoli elevatedexpressionofcdk4inlungcancer
AT wanghao elevatedexpressionofcdk4inlungcancer
AT zhouying elevatedexpressionofcdk4inlungcancer
AT liuzhen elevatedexpressionofcdk4inlungcancer
AT fangweiyi elevatedexpressionofcdk4inlungcancer
AT yangzhixiong elevatedexpressionofcdk4inlungcancer